vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $43.5M, roughly 1.3× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 7.6%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 9.8%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
DX vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $57.2M |
| Net Profit | — | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | — | -70.5% |
| Net Margin | — | -246.8% |
| Revenue YoY | 531.3% | 7.6% |
| Net Profit YoY | — | -2774.3% |
| EPS (diluted) | $1.59 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $57.2M | ||
| Q3 25 | $30.6M | $56.3M | ||
| Q2 25 | $23.1M | $52.6M | ||
| Q1 25 | $17.1M | $50.0M | ||
| Q4 24 | — | $53.2M | ||
| Q3 24 | — | $47.7M | ||
| Q2 24 | — | $50.5M | ||
| Q1 24 | $-3.2M | $47.5M |
| Q4 25 | — | $-141.2M | ||
| Q3 25 | $150.4M | $-22.6M | ||
| Q2 25 | $-13.6M | $-27.2M | ||
| Q1 25 | $-3.1M | $-29.5M | ||
| Q4 24 | — | $-4.9M | ||
| Q3 24 | — | $-5.3M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | $40.1M | $-4.1M |
| Q4 25 | — | -70.5% | ||
| Q3 25 | — | -55.6% | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -82.0% | ||
| Q4 24 | — | -19.3% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | — | -20.1% | ||
| Q1 24 | — | -19.5% |
| Q4 25 | — | -246.8% | ||
| Q3 25 | 491.3% | -40.1% | ||
| Q2 25 | -58.8% | -51.7% | ||
| Q1 25 | -18.0% | -58.9% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | — | -9.0% | ||
| Q1 24 | -1256.8% | -8.7% |
| Q4 25 | $1.59 | $-2.40 | ||
| Q3 25 | $1.08 | $-0.38 | ||
| Q2 25 | $-0.14 | $-0.46 | ||
| Q1 25 | $-0.06 | $-0.50 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | $0.64 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $327.2M |
| Total Assets | $17.3B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $84.9M | ||
| Q3 25 | $491.0M | $70.0M | ||
| Q2 25 | $387.5M | $81.0M | ||
| Q1 25 | $327.4M | $111.8M | ||
| Q4 24 | — | $102.3M | ||
| Q3 24 | — | $100.5M | ||
| Q2 24 | — | $103.0M | ||
| Q1 24 | $295.7M | $125.2M |
| Q4 25 | $2.5B | $327.2M | ||
| Q3 25 | $2.0B | $466.0M | ||
| Q2 25 | $1.6B | $486.3M | ||
| Q1 25 | $1.4B | $511.4M | ||
| Q4 24 | — | $538.5M | ||
| Q3 24 | — | $541.2M | ||
| Q2 24 | — | $542.5M | ||
| Q1 24 | $958.5M | $544.0M |
| Q4 25 | $17.3B | $488.9M | ||
| Q3 25 | $14.2B | $601.1M | ||
| Q2 25 | $11.3B | $624.7M | ||
| Q1 25 | $9.0B | $631.9M | ||
| Q4 24 | — | $656.2M | ||
| Q3 24 | — | $645.1M | ||
| Q2 24 | — | $651.4M | ||
| Q1 24 | $6.3B | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $-29.4M | ||
| Q3 25 | $68.3M | $-31.6M | ||
| Q2 25 | $31.9M | $-15.3M | ||
| Q1 25 | $6.4M | $-33.1M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | $-17.1M | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DX
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
